Company
Headquarters: New Taipei City, Taiwan
CEO: Dr. Lee-Cheng Liu
TW$28.62 Billion
TWD as of July 1, 2024
US$879.0 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
EirGenix Inc. operates as a contract development and manufacturing company Taiwan and internationally. Its services include cell line development and cell bank manufacturing, process development, analytical sciences and quality control, cGMP manufacturing, and antibody drug conjugate. The company was founded in 2012 and is based in New Taipei City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
EirGenix, Inc. has the following listings and related stock indices.
Stock: TWSE: 6589 wb_incandescent